• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu


Licensure of a DTaP-IPV Vaccine



DATE:January 27, 2008
FROM:Ronald Lundquist, Ph.D., OVRR/DVP/LMD
Licensure of a DTaP-IPV Vaccine
THROUGH:Konstantin Chumakov, Ph.D., OVRR/DVP/LMD
TO:The File

Recommendation: I recommend licensure of Kinrix, as described in BLA 125260.

I. Introduction-

GlaxoSmithKline Biologicals, S.A.(GSK), submitted BLA 125260, seeking approval for a United States license for Kinrix, their DTaP-IPV combination vaccine (diptheria and tetanus toxoids, acellular pertussis, absorbed, and inactivated poliovirus vaccine (IPV), combined) for the active immunization of children 4-6 years of age. This vaccine is intended to provide a fourth dose of IPV and a fifth dose of DTaP. Kinrix is fully preservative-free and does not contain either thimerosal or 2-phenoxyethanol (2-PE). Kinrix therefore differs from GSK's DTaP-IPV manufactured for other countries ( more than --------- lots to date), which contains 2-PE. The DTaP and IPV components of Kinrix are the same as those found in GSK's Pediarix (DTaP, IPV, and Hepatitis B (recombinant), combined), which was previously approved for use in the United States ( STN 103907, approved December 13, 2002). A single 0.5 ml dose of Kinrix will be administered in the deltoid muscle. Each dose contains------- of aluminum hydroxide as adjuvant, as does Pediarix. Kinrix is formulated to contain, per dose, 40/8/32 D units of Type 1 (Mahoney strain), Type 2 (MEF-1 strain), and Type 3 (Saukett strain) poliovirus antigens. The following review comments are focused on the IPV component of Kinrix.




Return to Approval History, Letters, Reviews, and Related Documents